Discontinuation of secondary prophylaxis against penicilliosis marneffei in AIDS patients after HAART

AIDS

Volumn 21, Issue 3, 2007, Pages 365-367

  Chaiwarith, Romanee ^a   Charoenyos, Noppawan ^a   Sirisanthana, Thira ^a   Supparatpinyo, Khuanchai ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; ITRACONAZOLE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LYMPHOCYTE COUNT; MALE; MYCOSIS; PENICILLIOSIS MARNEFFEI; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; MYCOSES; PENICILLIUM; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 33846591026     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000253374.19966.f9     Document Type: Article

References (11)

1. Sirisanthana T, Supparatpinyo K. Epidemiology and management of penicilliosis in human immunodeficiency virusinfected patients. Int J Infect Dis 1998; 3:48-53.
2. Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated Penicillium marneffei infection in southeast Asia. Lancet 1994; 344:110-113.
3. Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 2002; 34:277-284.
4. Sirisanthana T, Supparatpinyo K, Perriens J, Nelson KE. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 26:1107-1110.
5. Supparatpinyo K, Chiewchanvit S, Hirunsri P, Baosoung V, Uthammachai C, Chaimongkol B, Sirisanthana T. An efficacy study of itraconazole in the treatment of Penicillium marneffei infection. J Med Assoc Thai 1992; 75:688-691.
6. Supparatpinyo K, Perriens J, Nelson KE, Sirisanthana T. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. N Engl J Med 1998; 339:1739-1743.
7. Lopez Bernaldo de Quiros JC, Miro JM, Pena JM, Podzamczer D, Alberdi JC, Martinez E, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med 2001; 344:159-167.
8. Rollot F, Bossi P, Tubiana R, Caumes V, Zeller C, Katlama C, Bricaire F. Discontinuation of secondary prophylaxis against cryptococcosis in patients with AIDS receiving highly active antiretroviral therapy. AIDS 2001; 15:1448-1449.
9. El-Sadr WM, Burman WJ, Grant LB, Matts JP, Hafner R, Crane L, et al. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 2000; 342:1085-1092.
10. Goldman M, Zackin R, Fichtenbaum CJ, Skiest DJ, Koletar SL, Hafner R, et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis 2004; 38:1485-1489.
11. Hung CC, Chen MY, Hsieh SM, Sheng WH, Hsiao CF, Chang SC. Discontinuation of secondary prophylaxis for penicilliosis marneffei in AIDS patients responding to highly active antiretroviral therapy. AIDS 2002; 16:672-673.